PNT.US Tender Offer

Yosemite Falls Acquisition Corporation has offered to purchase all of the issued and outstanding shares of common stock of POINT BIOPHARMA GLOBAL INC. (PNT.US) at a price of US$12.50 per share, net to the stockholder in cash, without interest, and subject to any applicable withholding tax, upon the terms and subject to the conditions set forth in this purchase offer and related transfer instructions. Participants must obtain the Offer to Purchase, related Letter of Transmittal, and Schedule 14D-9, dated 13/10/2023 for complete terms and conditions of the offer. Participants should consult their tax advisor for complete details in reference to withholding taxes.

The terms of the offer are as follows:

Option (1): Take no action [Default option]

Option (2): Tender Shares – PRICE OF US$12.50 PER SHARE IN NET CASH (less any applicable withholding taxes)

The deadline to tender shares to the offer will be 14/11/2023@ 16:00 (HONG KONG TIME GMT+8).

In the absence of an election, no action will be taken.

Please fill in the following information and use the registered email address of Futu to send an email to cs@futuhk.com.

1. Account Number:
2. Name: (In Chinese or English)
3. Stock code: PNT.US
4. Options: (1) or (2)
5. Number of shares participating in corporate actions:

Note to applicants:
1. For shareholders holding less than 1 share of PNT.US, they cannot participate in related corporate actions.
2. Option (1) is the default option. We will help clients to choose option (1) if have not received clients’ emails.
3. Once the relevant application is submitted, the stocks participating in the company's actions cannot be traded and the application cannot be withdrawn.
4. This corporate action does not accept additional applications, the maximum number of applications that a client can apply for does not exceed the number of eligible shares it holds.
5. The pending orders and unsettled shares will not be accepted for the time being.
6. Please confirm that the account funds are sufficient to pay the relevant fees of this corporate action. Otherwise, we will not bear any responsibility for the failure of your application.
7. If there is any update, all the information released by the listed company shall prevail.